Flag of the European Union EU Clinical Trials Register Help

Clinical trials for glioblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    235 result(s) found for: glioblastoma. Displaying page 6 of 12.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2009-010576-21 Sponsor Protocol Number: CA180-274 Start Date*: 2009-08-26
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma
    Medical condition: recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Prematurely Ended) IT (Prematurely Ended) GB (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000095-15 Sponsor Protocol Number: OCTO_090 Start Date*: 2018-11-02
    Sponsor Name:University of Oxford
    Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab With Temozolomide Versus Temozolomide Alone after Surgery and Chemoradiotherapy in Patients with Recently Diagnosed Glioblastoma (IPI-GLIO)
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-004968-41 Sponsor Protocol Number: CPRC 2007-Dr BEAUCHESNE-TEMOFRAC Start Date*: 2008-02-06
    Sponsor Name:CHU DE NANCY - DIRECTION DE LA RECHERCHE CLINIQUE ET DE L'INNOVATION
    Full Title: Essai de phase II testant une association concomitante irradiation cérébrale ultra-fractionnée – témozolomide pour des glioblastomes multiformes inopérables de novo
    Medical condition: Glioblastomes multiformes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002775-28 Sponsor Protocol Number: GBM - ANOCEF01 Start Date*: 2008-10-06
    Sponsor Name:Centre Georges François Leclerc
    Full Title: Evaluation de l'association irinotécan/bévacizumab utilisée en néo-adjuvant et en adjuvant d'une radiochimiothérapie avec témozolomide concomitant pour les glioblastomes non résécables. Etude de ph...
    Medical condition: GLIOBLASTOMES MULTIFORME (GBM) NON RESECABLES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005428-81 Sponsor Protocol Number: P140402 Start Date*: 2015-07-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients with glioma positive for an FGFR fusion Relapsed/Refrac...
    Medical condition: Recurrent grade III or IV glioma with FGFR3-TACC3 or FGFR1-TACC1 fusion positive by RT-PCR
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004438-24 Sponsor Protocol Number: M14-483 Start Date*: 2015-06-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group.
    Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004015-31 Sponsor Protocol Number: WPD-201 Start Date*: 2021-09-10
    Sponsor Name:WPD Pharmaceuticals Sp. z o.o.
    Full Title: A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failur...
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001533-17 Sponsor Protocol Number: EORTC26053-22054 Start Date*: 2007-06-25
    Sponsor Name:EORTC European Organisation for research and treatment of cancer
    Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
    Medical condition: anaplastic glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003089-38 Sponsor Protocol Number: FG001-CT-001 Start Date*: 2020-09-03
    Sponsor Name:FluoGuide A/S
    Full Title: An open-label, dose escalation, single-dose administration, multi-center phase I/II trial of FG001 (an imaging agent), in patients with glioblastoma scheduled for neurosurgery
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003129-27 Sponsor Protocol Number: CBKM120E2102 Start Date*: 2014-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
    Medical condition: recurrent glioblastoma multiform
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001453-23 Sponsor Protocol Number: G-85974806 Start Date*: 2023-01-12
    Sponsor Name:ASATE
    Full Title: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma.
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013406-13 Sponsor Protocol Number: GBM-DC-2009 Start Date*: 2009-10-07
    Sponsor Name:Masaryk University
    Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study...
    Medical condition: Glioblastoma Multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002250-24 Sponsor Protocol Number: GCAR-7213 Start Date*: 2021-12-07
    Sponsor Name:Global Coalition for Adaptive Research
    Full Title: GCAR-7213: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Di...
    Medical condition: Oncology - Glioblastoma (GBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003659-40 Sponsor Protocol Number: CNS-201 Start Date*: 2022-01-03
    Sponsor Name:CNS Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multifor...
    Medical condition: Glioblastoma Multiforme (WHO Grade IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003193-10 Sponsor Protocol Number: CDKO-125a-002 Start Date*: 2009-02-24
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma
    Medical condition: Phase I Part: Recurrent Malignant Glioma Phase II Part: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065443 Malignant glioma LLT
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002410-31 Sponsor Protocol Number: GEINO-1602 Start Date*: 2018-02-06
    Sponsor Name:Grupo Español de Investigación en Neurooncología (GEINO)
    Full Title: Phase Ib/II Multicentric Study Combining Glasdegib with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination.
    Medical condition: Glasdegib (SHH pathway inhibitor) is a rational therapeutic agent for patients with newly diagnosed Glioblastoma since inhibits SHH pathway interfering with cancer stem cells and endothelial migrat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006288-36 Sponsor Protocol Number: 1200.24 Start Date*: 2009-03-16
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: Phase II open label trial to assess the efficacy and the impact on QTcF of continuous oral BIBW 2992 at a daily dose of 50 mg in patients with relapsed or refractory solid tumours including patient...
    Medical condition: Patients diagnosed with EGFR/HER2-positive solid tumour cancers with and without brain metastases, and patients with recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    9.1 10006128 Brain metastases LLT
    9.1 10049280 Solid tumour LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005169-78 Sponsor Protocol Number: P080301 Start Date*: 2009-02-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Traitement des récidives de glioblastomes par le SUTENT (SU11248) : essai de phase 2 avec étude translationnelle biologique et en imagerie
    Medical condition: Patients atteints de glioblastomes en récidive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 Glioblastomes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005549-12 Sponsor Protocol Number: P060102 Start Date*: 2007-05-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Chimiothérapie par Témozolomide dans le traitement des glioblastomes supratentoriels des sujets de 70 ans et plus présentant un état fonctionnel altéré (IK<70).
    Medical condition: Patients de 70 ans et plus atteints de glioblastomes supratentoriels et présentant un état fonctionnel altéré.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 glioblastome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014598-42 Sponsor Protocol Number: P081213 Start Date*: 2010-03-29
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Chimiothérapie par temozolomide-bevacizumab dans les glioblastomes supratentoriels des sujets de 70 ans et plus présentant un état fonctionnel altéré (IK < 70)
    Medical condition: Patients agés de 70 ans et plus atteints de glioblastome supratentoriel et présentant un état fonctionnel altéré (IK <70)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 glioblastomes PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 07:42:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA